Ding, X. et al. 2025. Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study. Acta Oncologica. 64, (May 2025), 607–615. DOI:https://doi.org/10.2340/1651-226X.2025.42652.